European Medicines' Agency launches new PRIME (PRIority MEdicines) scheme

The European Medicines Agency has launched the new PRIME (PRIority MEdicines) scheme on 7 March 2016, with the objective to strengthen support to medicines that target an unmet medical need.

The scheme focuses on medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients with no treatment options.

Through PRIME, the Agency offers early, proactive and enhanced support to medicine developers to optimise the generation of robust data on a medicine’s benefits and risks and enable accelerated assessment of marketing applications.

More information is available on the EMA's website.